## HoldiPharma reprices 160 drugs

In a bid to cut losses due to soaring production costs, the Holding Company for Pharmaceuticals (HoldiPharma) will raise the prices of 160 drugs made by its subsidiaries. In the first nine months of 2019, sales of state-owned drugmakers totaled EGP 1.6 billion, which is less than 50% of the Novartis figure of EGP 4 billion in sales. Nile Pharma topped the sales list of public pharma companies with EGP 300.1 million followed by Kahira Pharmaceuticals and Alex Pharma with EGP 277.8 million and EGP 243.1 million respectively.